{"hq_id":"hq-c-ino-000032","name":"Potassium bromate","context":"human_adult","timestamp":"2026-08-28T02:45:42.426Z","risk_level":"moderate_to_high","risk_profile":{"magnitude":{"mean":0.535816,"weightedMean":0.535816,"std_dev":0.178081,"confidence_interval_95":[0.5,0.8],"source_positions":[{"source":"EPA CTX / CalEPA","year":2021,"value":0.8,"weight":0.30176},{"source":"IARC","year":1999,"value":0.5,"weight":0.41},{"source":"HQ_DIRECT","year":2026,"value":0.35,"weight":0.35}]},"confidence":{"mean":0.714515,"weightedMean":0.714515,"std_dev":0.150427,"confidence_interval_95":[0.82,0.82],"source_positions":[{"source":"HQ_DIRECT","year":2026,"value":0.5,"weight":0.35},{"source":"IARC","year":1999,"value":0.82,"weight":0.41},{"source":"EPA CTX / CalEPA","year":2021,"value":0.82,"weight":0.30176}]},"recency":{"mean":0.627305,"weightedMean":0.627305,"std_dev":0.26675,"confidence_interval_95":[0.5,1],"source_positions":[{"source":"HQ_DIRECT","year":2026,"value":1,"weight":0.35},{"source":"IARC","year":1999,"value":0.5,"weight":0.41},{"source":"EPA CTX / CalEPA","year":2021,"value":0.368,"weight":0.30176}]},"methodology":{"mean":0.901108,"weightedMean":0.901108,"std_dev":0.141025,"confidence_interval_95":[1,1],"source_positions":[{"source":"HQ_DIRECT","year":2026,"value":0.7,"weight":0.35},{"source":"IARC","year":1999,"value":1,"weight":0.41},{"source":"EPA CTX / CalEPA","year":2021,"value":1,"weight":0.30176}]},"specificity":{"mean":0.806039,"weightedMean":0.806039,"std_dev":0.079914,"confidence_interval_95":[0.92,0.92],"source_positions":[{"source":"HQ_DIRECT","year":2026,"value":0.92,"weight":0.35},{"source":"IARC","year":1999,"value":0.75,"weight":0.41},{"source":"EPA CTX / CalEPA","year":2021,"value":0.75,"weight":0.30176}]},"consensus":{"exists":false,"strength":0,"disagreement_magnitude":0.314261,"warning":null}},"interpretation":{"summary":"Regulatory agencies show substantial disagreement. EPA CTX / CalEPA classifies as higher risk (80th percentile), while HQ_DIRECT concludes lower risk (35th percentile).","confidence_note":"Moderate-quality evidence base. Disagreement reflects methodological and interpretive differences, not data quality issues.","context_note":null,"warning":null},"sources":[{"id":"iarc_vol73_potassium_bromate_1999","type":"academic","title":"IARC Monographs Volume 73: Some Chemicals that Cause Tumours of the Kidney or Urinary Bladder in Rodents and Some Other Substances — Potassium Bromate, Group 2B Classification, Renal Carcinogenicity, and 8-OHdG Oxidative DNA Damage Mechanism (1999)","year":1999},{"id":"fda_potassium_bromate_bread","type":"regulatory","title":"US FDA: Potassium Bromate as Flour Improver — GRAS Status, Voluntary Withdrawal Policy, Residual Bromate in Finished Bread, and CSPI Petition History (2022)","year":2022},{"id":"efsa_potassium_bromate","type":"regulatory","title":"EFSA: Potassium Bromate — EU Prohibition as Food Additive (1990), Residual Monitoring in Imported Bread Products, and IARC 2B Classification Review (2005)","year":2005}],"sources_scope":"context","warnings":["year_inferred:EPA CTX / CalEPA:2021","unmapped_classification:EPA CTX / Genetox:genotoxicity: positive (ames: positive, 7 positive","unmapped_classification:EPA CTX / Genetox:genotoxicity: positive (ames: positive, 7 positive","unmapped_classification:EPA CTX / Skin-Eye:eye irritation: category 2b (score: moderate)","unmapped_classification:EPA CTX / Skin-Eye:eye irritation: category 6.4a (category 2a) (score","unmapped_classification:EPA CTX / Skin-Eye:skin irritation: category 6.3a (category 2) (score","unmapped_classification:EPA CTX / Skin-Eye:skin sensitisation: in vivo (llna): not likely to "],"meta":{"synthesis_version":"1.1.0","config_version":"1.1.0","n_sources":3,"db_version":38,"warnings":["year_inferred:EPA CTX / CalEPA:2021","unmapped_classification:EPA CTX / Genetox:genotoxicity: positive (ames: positive, 7 positive","unmapped_classification:EPA CTX / Genetox:genotoxicity: positive (ames: positive, 7 positive","unmapped_classification:EPA CTX / Skin-Eye:eye irritation: category 2b (score: moderate)","unmapped_classification:EPA CTX / Skin-Eye:eye irritation: category 6.4a (category 2a) (score","unmapped_classification:EPA CTX / Skin-Eye:skin irritation: category 6.3a (category 2) (score","unmapped_classification:EPA CTX / Skin-Eye:skin sensitisation: in vivo (llna): not likely to "]},"schema":"synthesis","_notice":"ALETHEIA output is reference data, not professional advice. Not a substitute for primary agency sources or qualified professionals. See https://aletheia.holisticquality.io/disclaimer.","_disclaimer_url":"https://aletheia.holisticquality.io/disclaimer","available_contexts":["human_adult","human_child","exposure_ingestion","human_teen","human_elderly","human_infant","human_pregnant"]}